Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy

C. Shad Thaxton, Robert Elghanian, Audrey D. Thomas, Savka I. Stoeva, Jae-Seung Lee, Norm D. Smith, Anthony J. Schaeffer, Helmut Klocker, Wolfgang Horninger, Georg Bartsch, Chad A. Mirkin

Research output: Contribution to journalArticle

265 Citations (Scopus)

Abstract

We report the development of a previously undescribed gold nanoparticle bio-barcode assay probe for the detection of prostate specific antigen (PSA) at 330 fg/mL, automation of the assay, and the results of a clinical pilot study designed to assess the ability of the assay to detect PSA in the serum of 18 men who have undergone radical prostatectomy for prostate cancer. Due to a lack of sensitivity, available PSA immunoassays are often not capable of detecting PSA in the serum of men after radical prostatectomy. This new biobarcode PSA assay is ≈300 times more sensitive than commercial immunoassays. Significantly, with the barcode assay, every patient in this cohort had a measurable serum PSA level after radical prostatectomy. Patients were separated into categories based on PSA levels as a function of time. One group of patients showed low levels of PSA with no significant increase with time and did not recur. Others showed, at some point postprostatectomy, rising PSA levels. The majority recurred. Therefore, this new ultrasensitive assay points to significant possible outcomes: (i) The ability to tell patients, who have undetectable PSA levels with conventional assays, but detectable and nonrising levels with the barcode assay, that their cancer will not recur. (ii) The ability to assign recurrence earlier because of the ability to measure increasing levels of PSA before conventional tools can make such assignments. (iii) The ability to use PSA levels that are not detectable with conventional assays to follow the response of patients to adjuvant or salvage therapies.

Original languageEnglish
Pages (from-to)18437-18442
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume106
Issue number44
DOIs
Publication statusPublished - 2009 Nov 3
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Nanoparticles
Recurrence
Immunoassay
Serum
Salvage Therapy
Automation
Gold
Prostatic Neoplasms

Keywords

  • Carcinoma of prostate
  • Prostate specific antigen

ASJC Scopus subject areas

  • General

Cite this

Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. / Thaxton, C. Shad; Elghanian, Robert; Thomas, Audrey D.; Stoeva, Savka I.; Lee, Jae-Seung; Smith, Norm D.; Schaeffer, Anthony J.; Klocker, Helmut; Horninger, Wolfgang; Bartsch, Georg; Mirkin, Chad A.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, No. 44, 03.11.2009, p. 18437-18442.

Research output: Contribution to journalArticle

Thaxton, CS, Elghanian, R, Thomas, AD, Stoeva, SI, Lee, J-S, Smith, ND, Schaeffer, AJ, Klocker, H, Horninger, W, Bartsch, G & Mirkin, CA 2009, 'Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy', Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 44, pp. 18437-18442. https://doi.org/10.1073/pnas.0904719106
Thaxton, C. Shad ; Elghanian, Robert ; Thomas, Audrey D. ; Stoeva, Savka I. ; Lee, Jae-Seung ; Smith, Norm D. ; Schaeffer, Anthony J. ; Klocker, Helmut ; Horninger, Wolfgang ; Bartsch, Georg ; Mirkin, Chad A. / Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. In: Proceedings of the National Academy of Sciences of the United States of America. 2009 ; Vol. 106, No. 44. pp. 18437-18442.
@article{58018ab6c9d048199d55d2c1582d4721,
title = "Nanoparticle-based bio-barcode assay redefines {"}undetectable{"} PSA and biochemical recurrence after radical prostatectomy",
abstract = "We report the development of a previously undescribed gold nanoparticle bio-barcode assay probe for the detection of prostate specific antigen (PSA) at 330 fg/mL, automation of the assay, and the results of a clinical pilot study designed to assess the ability of the assay to detect PSA in the serum of 18 men who have undergone radical prostatectomy for prostate cancer. Due to a lack of sensitivity, available PSA immunoassays are often not capable of detecting PSA in the serum of men after radical prostatectomy. This new biobarcode PSA assay is ≈300 times more sensitive than commercial immunoassays. Significantly, with the barcode assay, every patient in this cohort had a measurable serum PSA level after radical prostatectomy. Patients were separated into categories based on PSA levels as a function of time. One group of patients showed low levels of PSA with no significant increase with time and did not recur. Others showed, at some point postprostatectomy, rising PSA levels. The majority recurred. Therefore, this new ultrasensitive assay points to significant possible outcomes: (i) The ability to tell patients, who have undetectable PSA levels with conventional assays, but detectable and nonrising levels with the barcode assay, that their cancer will not recur. (ii) The ability to assign recurrence earlier because of the ability to measure increasing levels of PSA before conventional tools can make such assignments. (iii) The ability to use PSA levels that are not detectable with conventional assays to follow the response of patients to adjuvant or salvage therapies.",
keywords = "Carcinoma of prostate, Prostate specific antigen",
author = "Thaxton, {C. Shad} and Robert Elghanian and Thomas, {Audrey D.} and Stoeva, {Savka I.} and Jae-Seung Lee and Smith, {Norm D.} and Schaeffer, {Anthony J.} and Helmut Klocker and Wolfgang Horninger and Georg Bartsch and Mirkin, {Chad A.}",
year = "2009",
month = "11",
day = "3",
doi = "10.1073/pnas.0904719106",
language = "English",
volume = "106",
pages = "18437--18442",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "44",

}

TY - JOUR

T1 - Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy

AU - Thaxton, C. Shad

AU - Elghanian, Robert

AU - Thomas, Audrey D.

AU - Stoeva, Savka I.

AU - Lee, Jae-Seung

AU - Smith, Norm D.

AU - Schaeffer, Anthony J.

AU - Klocker, Helmut

AU - Horninger, Wolfgang

AU - Bartsch, Georg

AU - Mirkin, Chad A.

PY - 2009/11/3

Y1 - 2009/11/3

N2 - We report the development of a previously undescribed gold nanoparticle bio-barcode assay probe for the detection of prostate specific antigen (PSA) at 330 fg/mL, automation of the assay, and the results of a clinical pilot study designed to assess the ability of the assay to detect PSA in the serum of 18 men who have undergone radical prostatectomy for prostate cancer. Due to a lack of sensitivity, available PSA immunoassays are often not capable of detecting PSA in the serum of men after radical prostatectomy. This new biobarcode PSA assay is ≈300 times more sensitive than commercial immunoassays. Significantly, with the barcode assay, every patient in this cohort had a measurable serum PSA level after radical prostatectomy. Patients were separated into categories based on PSA levels as a function of time. One group of patients showed low levels of PSA with no significant increase with time and did not recur. Others showed, at some point postprostatectomy, rising PSA levels. The majority recurred. Therefore, this new ultrasensitive assay points to significant possible outcomes: (i) The ability to tell patients, who have undetectable PSA levels with conventional assays, but detectable and nonrising levels with the barcode assay, that their cancer will not recur. (ii) The ability to assign recurrence earlier because of the ability to measure increasing levels of PSA before conventional tools can make such assignments. (iii) The ability to use PSA levels that are not detectable with conventional assays to follow the response of patients to adjuvant or salvage therapies.

AB - We report the development of a previously undescribed gold nanoparticle bio-barcode assay probe for the detection of prostate specific antigen (PSA) at 330 fg/mL, automation of the assay, and the results of a clinical pilot study designed to assess the ability of the assay to detect PSA in the serum of 18 men who have undergone radical prostatectomy for prostate cancer. Due to a lack of sensitivity, available PSA immunoassays are often not capable of detecting PSA in the serum of men after radical prostatectomy. This new biobarcode PSA assay is ≈300 times more sensitive than commercial immunoassays. Significantly, with the barcode assay, every patient in this cohort had a measurable serum PSA level after radical prostatectomy. Patients were separated into categories based on PSA levels as a function of time. One group of patients showed low levels of PSA with no significant increase with time and did not recur. Others showed, at some point postprostatectomy, rising PSA levels. The majority recurred. Therefore, this new ultrasensitive assay points to significant possible outcomes: (i) The ability to tell patients, who have undetectable PSA levels with conventional assays, but detectable and nonrising levels with the barcode assay, that their cancer will not recur. (ii) The ability to assign recurrence earlier because of the ability to measure increasing levels of PSA before conventional tools can make such assignments. (iii) The ability to use PSA levels that are not detectable with conventional assays to follow the response of patients to adjuvant or salvage therapies.

KW - Carcinoma of prostate

KW - Prostate specific antigen

UR - http://www.scopus.com/inward/record.url?scp=70849093115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70849093115&partnerID=8YFLogxK

U2 - 10.1073/pnas.0904719106

DO - 10.1073/pnas.0904719106

M3 - Article

VL - 106

SP - 18437

EP - 18442

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 44

ER -